Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in nodenegative breast cancer

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1597-1602

  Iacopetta, Barry ^a   Grieu, Fabienne ^a   Powell, Brenda ^a   Soong, Richie ^a   McCaul, Kieran ^c   Seshadri, Ram ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c South Australian Health Commission   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EXONS; FEMALE; GENE AMPLIFICATION; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0031777159     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
2. Lane, D. P. p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
3. Bosari, S., and Viale, G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. A Pathol. Anat. Histopathol., 427: 229-241, 1995.
4. Allred, D. C., Clark, G. M., Elledge, R., Fuqua S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
5. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
6. Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 965-910, 1993.
7. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
8. Thorlacius, S., Borresen, A-L., and Eyfjord, J. E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res., 53: 1637-1641, 1993.
9. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Borresen, A-L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540-548, 1993.
10. Elledge, R. M., Fuqua, S. A., Clark, G. M., Pujol, P., Allred, D. C., and McGuire, W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res. Treat., 26: 225-235, 1993.
11. Seshadri, R., Leong, A. S., McCaul, K., Firgaira, F. A., Setlur, V., and Horsfall, D. J. Relationship between p53 gene abnormalities and other tumor characteristics in breast cancer prognosis. Int. J. Cancer, 69: 135-141, 1996.
12. Soong, R., Iacopetta, B., Harvey, J., Sterrett, G. F., Dawkins, H., Hahnel, R., and Robbins, P. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int. J. Cancer, 74: 642-647, 1997.
13. Shiao, Y-H., Chen, V. W., Scheer, W. D., Wu, X. C., and Correa, P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res., 55: 1485-1490, 1995.
14. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 1992.
15. Early Breast Cancer Trialist's Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N. Engl. J. Med., 333: 1444-1455, 1995.
16. Bergh, J. Time for integration of predictive factors for selection of breast cancer patients who need post-operative radiation therapy? J. Natl. Cancer Inst., 89: 605-607, 1997.
17. Soong, R., and Iacopetta, B. A rapid and non-isotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed paraffin embedded tumors. Mod. Pathol., 10: 252-58, 1997.
18. Seshadri, R., Firgaira, F., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol., 11: 1936-1942, 1993.
19. Horsfall, D. J., Tilley, W. D., Orell, S. R., Marshall, V. R., and Cant, E. L. M. Relationship between ploidy and steroid hormone receptors in primary breast cancer. Br. J. Cancer, 53: 23-28, 1986.
20. Bloom H. J., and Richardson, W. W. Histological grading and prognosis in breast cancer. Br. J. Cancer, 11: 359-377, 1957.
21. Cox, D. R. Regression models and life-tables. J. Royal Stat. Soc. B, 34: 187-220, 1972.
22. Kaplan E. L, and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
23. Mazars, R., Spinardi, L., Ben-Cheikh, M., Simony-Lafontaine, J., Jeanteur, P., and Theillet, C. p53 mutations occur in aggressive breast cancer. Cancer Res., 52: 3918-3923, 1992.
24. Jansson, T., Inganas, M., Sjogren, S., Norberg, T., Ljndgren, A., Holmberg, L., and Bergh, J. p53 status predicts survival in breast cancer patients treated with or without post-operative radiotherapy: a novel hypothesis based on clinical findings. J. Clin. Oncol., 13: 2745-2751, 1995.
25. Caleffi, M., Teague, M., Jensen, R., Vnencak-Jones, C., Dupont, W., and Parl, F. p53 gene mutations and steroid receptor status in breast cancer. Clinico-pathological correlations and prognostic assessment. Cancer (Phila.), 73: 2147-2156, 1994.
26. Marchetti, A., Buttita, F., Pellegrini, S., Campani, D., Diella, F., Ceccherti, D., Callahan, R., and Bistocchi, M. p53 mutations and histological type in invasive breast cancer. Cancer Res., 53: 4665-4669, 1993.
27. Gretarsdottir, S., Tryggvadottir, L., Jonasson, J., Sigurdsson, H., Olafsdottir, K., Agnarsson, B., Ogmundsdottir, H., and Eyfjord, J. E. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br. J. Cancer, 74: 555-561, 1996.
28. Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
29. Moyret, C., Theillet, C., Laurent-Puig, P., Moles, J., Thomas, G., and Hamelin, R. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene, 9: 1739-1743, 1994.
30. Iwahana, H., Fujimura, M., Takahashi, Y., Iwabuchi, T., Yoshimoto, K., and Itakura, M. Multiple fluorescence-based PCR-SSCP analysis using internal fluorescent labelling of PCR products. BioTechniques, 21: 510-519, 1996.
31. Silvestrini, R., Veneroni, S., Benini, E., Daidone, M., Luisi, A., Leutner, M., Maucione, A., Kenda, R., Zucali, R., and Veronesi, U. Expression of p53, glutathione S-transferase-π, and bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J. Natl. Cancer Inst., 89: 639-645, 1997.